Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

Purchaser coalition data show accelerating uptake: direct contracts rose from 18.7% (2023) to 27.6% (2025), with an additional 26.7% evaluating adoption over one to three years. Cost pressure remains ...

In a fifth segment from an extended interview with Managed Healthcare Executive, Jaewon Ryu, M.D., J.D., identified the Care Without Delay program and the value-based care guides as central elements ...

In multivariable analysis, six clinicopathologic variables were significantly associated with time to recurrence: ulceration, tumor thickness, tumor location, neurotropism (tumor growth along nerves), ...

IBX’s Rodrigo Cerdá, M.D., M.P.H., back Jefferson Health primary care screening to catch dementia care needs early and coordinate support.